Skip to Content

Trandolapril / verapamil Side Effects

Commonly reported side effects of trandolapril/verapamil include sinus bradycardia. Other side effects include first degree atrioventricular block, bradycardia, and second degree atrioventricular block. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to trandolapril / verapamil: oral tablet extended release

As well as its needed effects, trandolapril / verapamil may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking trandolapril / verapamil, check with your doctor immediately:

  • Chest pain
  • chills
  • cough (with mucus)
  • dark urine
  • fever
  • general feeling of discomfort or illness
  • lightheadedness or fainting
  • pain in the right side of the abdomen or stomach
  • shortness of breath
  • slow heartbeat
  • sore throat
  • swelling of the face, mouth, hands, or feet
  • trouble in swallowing or breathing (sudden) accompanied by hoarseness
  • wheezing
  • yellow eyes or skin

Some trandolapril / verapamil side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

Less common or rare
  • Constipation
  • cough (dry, continuing)
  • diarrhea
  • dizziness
  • itching
  • joint pain or pain in the arms or legs
  • nausea
  • unusual tiredness

For Healthcare Professionals

Applies to trandolapril / verapamil: oral tablet extended release


In general, side effects associated with this combination drug have been mild and transient. Side effects associated with each component of this drug may be observed. Discontinuation of therapy because of adverse events in US placebo-controlled hypertension studies was required in 2.6% and 1.9% of patients receiving drug and placebo, respectively. Postmarketing reports have included malaise and fever.[Ref]


The use of trandolapril-verapamil in some patients with depressed left ventricular systolic function and atrial fibrillation is somewhat controversial because verapamil can (1) accelerate AV conduction, particularly in patients with an accessory AV nodal pathway (e.g., Wolff-Parkinson-White or Lown-Ganong-Levine syndromes) and (2) further depress LV systolic function. In general, verapamil is not recommended for patients with atrial fibrillation and premature ventricular depolarizations.

Angina pectoris has been reported in as many as 36% of patients in the Trandolapril Cardiac Evaluation (TRACE) study, but the incidence of underlying coronary artery disease in the patient population studied was essentially 100% (patients with a history of myocardial infarction). Moreover, the incidence of angina pectoris among placebo patients in the TRACE study was 38% (not significantly different).[Ref]

Cardiovascular side effects including 1st-degree AV heart block in 3.9%, sinus bradycardia in 1.8%, chest pain in 2.2% (any origin), dizziness in 3.1%, and edema in 1.3% of patients have been reported. Verapamil may have negative inotropic activity, and may induce or exacerbate congestive heart failure in 2% of patients. This may be particularly important in elderly patients and in patients with tenuous left ventricular (LV) systolic function and/or who are also taking a beta-blocker. Postmarketing side effects include myocardial infarction, myocardial ischemia, angina pectoris, cardiac failure, ventricular tachycardia, tachycardia, transient ischemic attack, and arrhythmia.[Ref]


Gastrointestinal side effects may be related to the verapamil component. Constipation has been reported in 3.3% (up to 7% of patients on verapamil alone), nausea in 3%, and diarrhea in 1.5% of patients. Constipation can often be controlled by increasing dietary fiber. Postmarketing reports have included dry mouth and pancreatitis.[Ref]

Less common side effects associated with verapamil, as well as some other calcium channel blockers, include gingival hyperplasia, diarrhea, dry mouth, and dyspepsia. Trandolapril has rarely been associated with vomiting, appetite or weight changes, and dry mouth in approximately 0.5% of patients.[Ref]


Respiratory side effects including cough, a common respiratory system side effect associated with angiotensin converting enzyme (ACE) inhibitors, have been reported in up to 5% of patients who receive trandolapril-verapamil. The incidence of dyspnea among patients in controlled trials averages 1.3% among patients who received the drug, compared with 0% of patients on placebo. Postmarketing reports have included bronchitis.[Ref]

Nervous system

Nervous system side effects include dizziness (possibly related to drug-induced hypotension) in 3.1%, fatigue in 2.8%, and headaches in 8.9% of patients. The incidence of the latter two side effects were comparable to placebo in controlled studies. Postmarketing reports have included cerebral hemorrhage.[Ref]

Trandolapril has also been associated with sleep or taste disturbances, nervousness, mood changes, tinnitus, asthenia, or anxiety in approximately 2% of patients.[Ref]


Hepatic side effects including elevated hepatic transaminase and alkaline phosphatase enzymes have been reported in 2.8% of patients. Hepatic side effects associated with the use of ACE inhibitors have included a rare syndrome that begins with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. Experts recommend discontinuation of therapy with this drug if jaundice or markedly elevated hepatic serum enzymes develop. The use of verapamil monotherapy has rarely been associated with significant hepatotoxicity. Postmarketing reports include elevated liver transaminases, elevated bilirubin, jaundice and hepatitis.[Ref]

The mechanism of hepatic injury associated with verapamil is not known; in some cases, the mechanism is considered either idiosyncratic or due to hypersensitivity.[Ref]


Renal side effects including new or worsened renal insufficiency have been associated with the use of ACE inhibitors, particularly in patients with underlying cardiovascular or renal disease.
Postmarketing reports have included renal failure, elevated creatinine, and elevated blood urea nitrogen.[Ref]


Angioedema associated with laryngeal edema can be fatal. If laryngeal stridor or angioedema of the face, tongue or glottis occurs, trandolapril should be discontinued immediately, the patient treated in accordance with accepted medical care and carefully observed until the swelling disappears. In cases where the swelling is confined to the face and lips, the condition generally resolves without treatment; antihistamines may be useful in relieving symptoms. Where there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, emergency therapy, including, but not limited to subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) should be administered promptly.

Patients with intestinal angioedema generally present with abdominal pain (with or without nausea or vomiting) and in some cases there was no prior history of facial angioedema, and C-1 esterase levels were normal. These symptoms resolve after stopping the ACE inhibitor.[Ref]

Hypersensitivity reactions to angiotensin converting enzyme (ACE) inhibitors may be life threatening. Angioedema of the face, extremities, lips, tongue, glottis and/or pharynx have been reported rarely in patients receiving ACE inhibitors. In addition, intestinal angioedema has been reported in patients treated with ACE inhibitors. It is recommended that any patient with dyspnea, dysphagia, or significant facial angioedema stop therapy immediately and avoid ACE inhibitor therapy in general. Urticaria, rash, pemphigus, pruritus, and photosensitivity have been reported in less than 1% of patients who received trandolapril.[Ref]


Metabolic side effects associated with ACE inhibitors include mild hyperkalemia, the result of inhibition of aldosterone secretion. Postmarketing reports include hyponatremia.[Ref]


Hematologic problems rarely reported with some ACE inhibitors include agranulocytosis and bone marrow depression. Postmarketing reports have included thrombocytopenia, agranulocytosis and pancytopenia.[Ref]


Musculoskeletal pains have been rarely associated with trandolapril-verapamil.[Ref]


Genitourinary complaints associated with verapamil monotherapy appear to be limited to rare cases of sexual impotence and loss of libido among males.[Ref]


Endocrine side effects as a result of verapamil have included hyperprolactinemia and galactorrhea.[Ref]

Although the mechanism is not known, verapamil may interfere with the release or synthesis of prolactin inhibitor factor in the hypothalamus. Due to verapamil-induced hyperprolactinemia, rare cases of galactorrhea have been reported in both men and women.[Ref]


Dermatologic side effects have included postmarketing reports of alopecia, sweating, Stevens-Johnson syndrome and toxic epidermal necrolysis.[Ref]


Psychiatric side effects have included postmarketing reports of hallucination and depression.[Ref]


1. "Product Information. Tarka (trandolapril-verapamil)." Knoll Pharmaceutical Company, Whippany, NJ.

2. Wiseman LR, McTavish D "Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension." Drugs 48 (1994): 71-90

3. De Ponti F, Marelli C, D'Angelo L, Caravaggi M, Bianco L, Lecchini S, Frigo GM, Crema A "Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers." Eur J Clin Pharmacol 40 (1991): 149-53

4. Raftos J "Verapamil in the long-term treatment of angina pectoris." Med J Aust 07/26/80 (1980): 78-80

5. Gaillard CA, de Leeuw PW "Clinical experiences with trandolapril." Am Heart J 125 (1993): 1542-6

6. Vaur L, Dutrey-Dupagne C, Boussac J, Genes N, Bouvier d'Yvoire M, Elkik F, Meredith PA "Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients." J Cardiovasc Pharmacol 26 (1995): 127-31

7. Schwartz JB, Jeang M, Raizner AE, et al "Accelerated junctional rhythms during oral verapamil therapy." Am Heart J 107 (1984): 440-3

8. Schwartz JB "Verapamil in atrial fibrillation: the expected, the unexpected, and the unknown." Am Heart J 106 (1983): 173-6

9. Jacob AS, Nielsen DH, Gianelly RE "Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome with atrial fibrillation." Ann Emerg Med 14 (1985): 159-60

10. Bevan EG, McInnes GT, Aldigier JC, Conte JJ, Grunfeld JP, Harper SJ, Meyer BH, Pauly N, Wilkinson R "Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril." Br J Clin Pharmacol 35 (1993): 128-35

11. Frishman WH, Eisen G, Charlap S, Strom JA "Long-term safety and efficacy of immediate-release and sustained-release oral verapamil in systemic hypertension." J Clin Hypertens 3 (1987): 605-9

12. Stehle G, Buss J, Eibach J, et al "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990): 1079

13. Hame A, Peter T, Platt M, Mandel WJ "Effects of verapamil on supraventricular tachycardia in patients with overt and concealed wolff-parkinson-white syndrome." Am Heart J 101 (1981): 600-12

14. Mooy J, Schols M, Baak MV, et al "Pharmacokinetics of verapamil in patients with renal failure." Eur J Clin Pharmacol 28 (1985): 405-10

15. Pollak A, Falk RH "Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis." Chest 104 (1993): 618-20

16. Pritza DR, Bierman MH, Hammeke MD "Acute toxic effects of sustained-release verapamil in chronic renal failure." Arch Intern Med 151 (1991): 2081-4

17. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995): 1670-6

18. Echizen H, Vogelgesang B, Eichelbaum M "Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism." Clin Pharmacol Ther 38 (1985): 71-6

19. Weiner DA, McCabe CH, Cutler SS, et al "Efficacy and safety of verapamil in patients with angina pectoris after 1 year of continuous, high-dose therapy." Am J Cardiol 51 (1983): 1251-5

20. Fornes P, Richer C, Pussard E, Heudes D, Domergue V, Giudicelli JF "Beneficial effects of trandolapril on experimentally induced congestive heart failure in rats." Am J Cardiol 70 (1992): d43-51

21. Winters SL, Schweitzer P, Kupersmith J, Gomes JA "Verapamil-induced polymorphous ventricular tachycardia." J Am Coll Cardiol 6 (1985): 257-9

22. McTavish D, Sorkin EM "Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension." Drugs 38 (1989): 19-76

23. Baky SH, Singh BN "Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics." Pharmacotherapy 2 (1982): 328-50

24. Panidis IP, Morganroth J, Baessler C "Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis." Am J Cardiol 52 (1983): 1197-201

25. Bursztyn M, Ghanem J, Kobrin I, et al "Comparison of verapamil and captopril in elderly hypertensive subjects: results of a randomized, double-blind, crossover study." J Cardiovasc Pharmacol 21 (1993): 84-8

26. Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996): 921-8

27. Brogden RN, Benfield P "Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease." Drugs 51 (1996): 792-819

28. Guller B, Hall J, Reeves RL "Cardiac effects of trandolapril in hypertension." Am Heart J 125 (1993): 1536-41

29. McGovern B, Garan H, Ruskin JN "Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome." Ann Intern Med 104 (1986): 791-4

30. Arstall MA, Beltrame JF, Mohan P, Wuttke RD, Esterman AJ, Horowitz JD "Incidence of adverse events during treatment with verapamil for suspected acute myocardial infarction." Am J Cardiol 70 (1992): 1611-2

31. "Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company, Whippany, NJ.

32. Shimoni A, Maorkendler Y, Neuman Y "Verapamil-induced acute right heart failure." Am Heart J 132 (1996): 193-4

33. Saikawa T, Inoue K, Ohmura I, et al "The paradoxical adverse effect of verapamil for treating clinical paroxysmal supraventricular tachycardia." Jpn Heart J 28 (1987): 107-13

34. Lewis GR "Long-term results with verapamil in essential hypertension and its influence on serum lipids." Am J Cardiol 57 (1986): d35-8

35. Davis PJ, Fagan TC, Topmiller MJ, Levine JH, Ferdinand KC "Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil." J Clin Pharmacol 35 (1995): 52-8

36. Mancia G, De Cesaris R, Fogari R, Lattuada S, Montemurro G, Palombo C, Porcellati C, Ranieri G, Tettamanti F, Verdecchia P, et al "Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring. The Italian Trandolapril Study Group." Am J Cardiol 70 (1992): d60-6

37. Zachariah PK, Sheps SG, Oshrain C, et al "Antihypertensive efficacy of sustained-release verapamil." J Clin Hypertens 3 (1987): 536-46

38. Steele RM, Schuna AA, Schreiber RT "Calcium antagonist-induced gingival hyperplasia." Ann Intern Med 120 (1994): 663-4

39. Doughty JC, Donald AK, Keogh G, Cooke TG "Stercoral perforation with verapamil." Postgrad Med J 70 (1994): 525

40. Guttenberg SA "Chemical injury of the oral mucosa from verapamil." N Engl J Med 323 (1990): 615

41. Zlotogorski A "Calcium blockers and gingival hyperplasia." Oral Surg Oral Med Oral Pathol Sept (1991): 316

42. Krevsky B, Maurer AH, Niewiarowski T, Cohen S "Effect of verapamil on human intestinal transit." Dig Dis Sci 37 (1992): 919-24

43. Kamei J, Iwamoto Y, Misawa M "Cough-induced activity of (-)-(2S, 3aR, 7aS)-1-[(S)-N-[(S)-1- ethoxycarbonyl-3- phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolapril) in guinea pigs." Res Commun Mol Pathol Pharmacol 85 (1994): 105-8

44. Radhakrishnan S, Talwar KK, Kaushal R, Bhatia ML "Respiratory arrest with intravenous verapamil." Am Heart J 111 (1986): 622

45. Jacobsen FM, Sack DA, James SP "Delirium induced by verapamil." Am J Psychiatry 144 (1987): 248

46. Dassylva B "Verapamil may cause depression." Can J Psychiatry 38 (1993): 299-300

47. Rosansky SJ "Verapamil toxicity: treatment with hemoperfusion." Ann Intern Med 114 (1991): 340-1

48. Padrell MD, Navarro M, Faura CC, Horga JF "Verapamil-induced parkinsonism." Am J Med 99 (1995): 436

49. Shah AR, Passalacqua BR "Case report: sustained-release verapamil overdose causing stroke: an unusual complication." Am J Med Sci 304 (1992): 357-9

50. Patat A, Surjus A, Le Go A, Granier J "Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor." Eur J Clin Pharmacol 36 (1989): 17-23

51. Hicks CB, Abraham K "Verapamil and myoclonic dystonia." Ann Intern Med 103 (1985): 154

52. Reverte M "Adverse effect of verapamil in myasthenia gravis: an additional comment." Muscle Nerve 16 (1993): 879-81

53. Thomke F, Vogt T, Roder R, Hopf HC "Fasciculations due to verapamil in a patient with neuropathy." J Neurol 237 (1990): 448-9

54. Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982): 612-3

55. Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981): 490-1

56. Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986): 610-11

57. Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994): 485-6

58. Nash DT, Feer TD "Hepatic injury possibly induced by verapamil." JAMA 249 (1983): 395-6

59. Guarascio P, D'Amato C, Sette P, et al "Liver damage from verapamil." Br Med J 288 (1984): 362-3

60. Predel HG, Rohden C, Heine O, Rost RE "Influence of the nonsulfhydryl angiotensin-converting enzyme inhibitor trandolapril on lipid and carbohydrate metabolism related to exercise capacity in healthy subjects." Am Heart J 125 (1993): 1532-5

61. Kumana CR, Mahon WA "Bizarre perceptual disorder of extremities in patients taking verapamil." Lancet 06/13/81 (1981): 1324-5

62. King BD, Pitchon R, Stern EH, et al "Impotence during therapy with verapamil." Arch Intern Med 143 (1983): 1248-9

63. Gluskin LE, Strasberg B, Shah JH "Verapamil-induced hyperprolactinemia and galactorrhea." Ann Intern Med 95 (1981): 66-7

64. Fearrington EL, Rand CH, Rose JD "Hyperprolactinemia-galactorrhea induced by verapamil." Am J Cardiol 51 (1983): 1466-7

65. Peer G, Korzets A, Levtov O "Plasma lipid profile in verapamil-treated hypertensive patients." Int J Clin Pharmacol Ther Toxicol 25 (1987): 489-92

66. Thomas SH, Stone CK, May WA "Exacerbation of verapamil-induced hyperglycemia with glucagon." Am J Emerg Med 13 (1995): 27-9

67. Dombrowski RC, Romeo JH, Aron DC "Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma." Ann Pharmacother 29 (1995): 999-1001

68. Romeo JH, Dombrowski R, Kwak YS, Fuehrer S, Aron DC "Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men." Clin Endocrinol (Oxf) 45 (1996): 571-5

It is possible that some side effects of trandolapril / verapamil may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.